



EXPRESS SCRIPTS®

January 23, 2017

The Honorable Daniel Hawkins  
Chairman, House Health and Human Services Committee  
Kansas Legislature  
Topeka, Kansas

Dear Chairman Hawkins & Members of the Committee:

Thank you for the opportunity to submit written testimony in support of House Bill 2107, which will allow for the substitution of FDA-approved interchangeable biologics.

Express Scripts is the nation's largest pharmacy benefits manager, providing the prescription drug benefit for over 85 million Americans. Our company's mission is to make the use of prescription drugs safer and more affordable, and this legislation supports that endeavor.

Over the past several years Express Scripts has worked with the pharmaceutical manufacturing community and other stakeholders in an attempt to broker an equitable solution on the issue of interchangeable biologics. The results of those efforts are before you in HB 2107, with the electronically-based communication provisions in Section 3 of the bill being a key to successfully forging consensus and enacting this important legislation in a growing number of states.

HB 2107 will allow for a robust biosimilars market, while simultaneously protecting both patients and payors. Enacting this bill into law will mean that Kansas' law will be updated to permit its residents to take full advantage of interchangeable biologics, as they become available.

The first biosimilars have been approved by the FDA. A further wave of drug products in the pipeline that may be approved by the FDA should reduce prescription drug spending by hundreds of billions of dollars over the next decade.

Express Scripts enthusiastically supports HB 2107 and we appreciate the Committee's consideration of this important measure.

Michael Harrold  
Senior Director, State Government Affairs  
Express Scripts  
One Express Way  
St. Louis, MO 63121  
[Mdharrold@express-scripts.com](mailto:Mdharrold@express-scripts.com)